Saura, C., Oliveira, M., Feng, Y., Dai, M., Chen, S., Hurvitz, S. A., . . . Brufsky, A. (2020). Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial. J Clin Oncol.
Chicago Style CitationSaura, Cristina, et al. "Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial." J Clin Oncol 2020.
MLA CitationSaura, Cristina, et al. "Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial." J Clin Oncol 2020.